Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Hyloris Pharmaceuticals SA ( (DE:52U) ) is now available.
Hyloris Pharmaceuticals has signed an exclusive licensing agreement to develop a ready-to-use intravenous formulation of pantoprazole, a drug used to treat gastric acid-related conditions. This new formulation simplifies administration, reduces preparation time, and improves cost efficiency, potentially capturing a significant market share and enhancing patient care globally.
More about Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is a specialty biopharma company focused on addressing unmet medical needs by reinventing existing medications. The company is committed to advancing healthcare delivery through innovative solutions.
YTD Price Performance: -22.97%
Average Trading Volume: 299
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €165.2M
Find detailed analytics on 52U stock on TipRanks’ Stock Analysis page.